NYSE MKT LLC · CLDI
-4.39% · -$0.0597 · Vol Not reported
Pre-market · updated 06:48:47 ET
Calidi Biotherapeutics Inc

Calidi Biotherapeutics Inc

Biotechnology
$1.30
Card
Relationship Map

Veridion Score

BETALOW CONF · 6/6 factorsMethodology
CLDI
Calidi Biotherapeutics Inc
Mon Aug 17 · last completed session · Pre-market · regular session opens 9:30 ET
NEUTRAL

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

59/ 100
Veridion Score
NEUTRAL · LOW confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 6/6 factors with data · Mon Aug 17 · last completed session · Pre-market · regular session opens 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is CLDI moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading CLDI catalysts
About Calidi Biotherapeutics Inc
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed since
2023
Employees
29
Country
US

Calidi Biotherapeutics Inc is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company's proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. Its technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations. Its product candidates include The RedTail for Metastatic Solid Tumors, CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-101 (NeuroNova) for Newly Diagnosed High Grade Glioma.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$1.36
Last session
Day high
$1.36
Last session
Day low
$1.36
Last session
Previous close
$1.36
52W high
$65.60
-98.02% from high
52W low
$1.30
0% of range
Market cap
$3.9M
EPS
$-7.5700
Beta
0.02
Shares out
2.4M
Avg volume
375.6K
VWAP
$1.36
Last session
Price history computed in-house
1W
-20.71%
1M
-31.65%
3M
-52.00%
1Y
-98.02%
YTD
-93.05%
SMA 50 $2.13 · below
SMA 200 $10.10 · below
52W position 0%

CLDI overview

Veridion Score
59
Daily close · 2026-08-17
6 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around CLDI.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading CLDI Form 4 filings
Public disclosures

Congress activity in CLDI

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for CLDI in the cached public ledger.

Federal contracts

CLDI contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for CLDI in this window.
Lobbying spend

CLDI lobbying filings, year to date.

Registered lobbying filings matched to Calidi Biotherapeutics Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for CLDI in this window.
Loading news for CLDI
Analyst ratings
Sovereign unlock shows live analyst consensus for CLDI.
Options
Sovereign unlock shows live options positioning for CLDI.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.